Printer Friendly Version

Send to a Friend

Emergent BioSolutions dedicated its 50,000-sf vaccine production plant in Lansing, Mich., on July 21, 2006. The $75-million, three-story facility will enable the company to expand production capacity for its anthrax vaccine, BioThrax®, as well as providing space for future immunobiotics development. Construction on the plant began in February 2006 and is expected to reach completion in early 2007, with FDA certification slated for 2008. The 24/7/365 facility will accommodate 275 employees. Emergent BioSolutions is part of BioPort Corporation.